In the clinic for Oct. 23, 2023
Original source here.
|Exact Sciences Corp., of Madison, Wis.||Cologuard||Stool DNA test||Colorectal cancer (CRC)||Data from the pivotal BLUE-C trial showed the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for CRC at 91% specificity; the test was significantly more likely to detect cancer or precancer than fecal immunochemical testing (FIT) (94% vs. 67% and 43% vs. 23%, respectively)|
|Guardant Health Inc., of Palo Alto, Calif.||Guardant Reveal||Circulating tumor DNA blood test||Colon cancer||Initial results from the PEGASUS trial suggest Guardant Reveal may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer; 34% of patients with a positive liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse|
|Oncohost Ltd., of Binyamina, Israel||Prophet test||Proteomics-based decision-support tool||Non-small-cell lung cancer||Study examining the experimental and computational analytical validity of the test was published in the Journal of Pharmaceutical & Biomedical Analysis; a strong experimental precision and accuracy performance was observed; computational precision analysis displayed high consistency for repeated samples; cross-platform analysis supported the reliability of the examined proteomic assay|
For more information about individual companies and/or products, see Cortellis.